Pharmerit International Celebrates 10 Years
Since 2000, Pharmerit international has evolved from a small research consultancy firm to a thriving business with an international scope, offering a comprehensive range of research activities, including health economics evaluations & modeling, outcomes research, comparative effectiveness, meta-analyses, market access, pricing & reimbursement research, health economic & reimbursement dossiers and strategic positioning & health policy research
"What started out 10 years ago has steadily grown into a business far exceeding anyone's expectations" said Lex Tergau, co-founder and managing partner. "We are all very proud of this accomplishment and grateful to our clients and employees who helped us get there" read more
ISPOR Meeting, Atlanta, May 15-19, 2010
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) meeting offers an ideal opportunity for sharing knowledge and new developments, and discussing them with others in the field of health economics and outcomes research. Are you interested in what research we are conducting? Please visit our booth (no. #1-2), or visit one of the Pharmerit-sponsored Internet Access Stations.
Pharmerit’s Staff Contributions to ISPOR 15th Annual International Meeting in Atlanta, Georgia, USA:
Short Course
Saturday May 15th, 13:00 - 17:00
Modeling: Design and structure of a model
Research Presentations
Session I, Monday May 17th, 13:45 – 14:45
Research on Pro Methods - Utility methods: Evaluating the measurement properties of an augmented EQ-5D with the inclusion of two single QoL indicators using the MEPS
Poster Presentations
Session I, Monday May 17th, 18:30 - 19:30
Diabetes/Endocrine Disorders: Assessing the impact of painful diabetic peripheral neuropathy or post-herpetic neuralgia related health impairment on loss of productive time(PDB36)
Session II, Tuesday May 19th, 18:00 - 19:00
Mental Health: Discrete event simulation model in major depressive disorder: life-time health outcomes of adjunctive atypical antipsychotics (PMH11) The comparative efficacy and safety of adjunctive antipsychotics in major depressive disorder patients that failed to respond to conventional antidepressants (PMH16)
Neurological Disorders: The value of a predictive diagnostic blood test in multiple sclerosis (PND2)
Session III, Wednesday May 20th, 9:30 - 10:30
Urinary/Kidney Disorders: Cost-effectiveness analysis of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder: application to the United Kingdom (PUK9)
,